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Background: In primary cutaneous melanoma, the sentinel node (SN) biopsy is an accurate method
for the staging of the lymph nodes. Positron emission tomography (PET) has been suggested as a use-
ful alternative. However, the sensitivity of PET may be too low to detect SN metastases, which are often
small.
Aim: To predict the value of PET for initial lymph node staging in melanoma based on morphometric
analysis of SN metastatic load, without exposing patients to PET.
Material and methods: In 59 SN positive patients with melanoma, the sizes of tumour deposits in the
SNs and subsequent dissection specimens were measured by morphometry and correlated with the
detection limits of current and future PET scanners.
Results: The median tumour volume within the basin was 0.15 mm3 (range, 0.0001–118.86). Seventy
per cent of these deposits were smaller than 1 mm3. State of the art PET scanners that have a resolution
of about 5 mm would detect only 15–49% of positive basins. Logistic regression analysis revealed no
pretest indicators identifying patients expected to have a positive PET. However, the SN tumour load
was a significant and single predictor of the presence of PET detectable residual tumour.
Conclusion: Morphometric analysis of metastatic load predicts that PET scanning is unable to detect
most metastatic deposits in sentinel lymph nodes of patients with melanoma because the metastases are
often small. Therefore, the SN biopsy remains the preferred method for initial regional staging.
Determining the metastatic spread of tumour cells to theregional lymph nodes is essential in the assessment ofprognosis and treatment options in patients with
primary cutaneous melanoma. The sentinel node (SN) biopsy
is currently the standard method for initial regional staging
and has replaced the elective lymph node dissection.1 The SN
is the first tumour draining lymph node that is surgically
removed at the time of wide local excision of the primary
melanoma. When the SN is tumour positive, a complete
regional lymph node dissection (LND) is performed, but when
the SN is negative, further regional lymph nodes should be
negative in theory, and can therefore be left in situ.2–6
Positron emission tomography (PET) is a relatively new
diagnostic imaging modality that allows the characterisation
of disease based on altered metabolism rather than on the
presence of structural abnormality. Accordingly, it differs fun-
damentally from most conventional imaging modalities, such
as x ray films, computed tomography, and magnetic resonance
imaging. In contrast, whole body PET can detect malignancy
in normal sized lymph nodes and examines all organ systems
in a single procedure.7–9 Images are obtained from positron
emitting radioactive tracers that are administered intrave-
nously. In oncology, 18F-fluorodeoxyglucose (FDG) is most fre-
quently used because of the enhanced glucose consumption
by tumours.10 The avidity of FDG for melanoma cells and the
superior sensitivity of PET scanners led to the suggestion that
FDG-PET might be used for initial non-invasive locoregional
staging in breast cancer11 and cutaneous melanoma.12–15 One
PET study claimed that micrometastases in SNs can be
detected by PET before surgery.15 However, in breast cancer,
this has already been questioned.16 Accurate assessment by
PET of locoregional lymph nodes (LNs) would have great
advantages: in LN positive patients, one could perform a
primary lymph node dissection and avoid the SN procedure.
The amount of (residual) tumour and the response to
treatment are of importance when systemic treatment is con-
sidered. Such information would be very important because it
could save unnecessary patient suffering and high costs, and
could provide essential prognostic information for therapeutic
decision making.
“Positron emission tomography is a relatively new diag-
nostic imaging modality that allows the characterisation
of disease based on altered metabolism rather than on
the presence of structural abnormality”
Even though it has convincingly been shown that PET
detects tumour deposits smaller than the 1 cm limit of the
computed tomography scan,17 the detectability rapidly de-
creases below the system resolution (typically 5 mm for a state
of the art scanner). Therefore, we have analysed the size of
metastatic lymph node deposits in histological sections by
morphometry, and compared these with PET resolution. We
also investigated whether future PET scanning machines will
ever be able to detect micrometastases, given the detection
limits that can be anticipated.
PATIENTS AND METHODS
Patients
Data were analysed from a cohort of 308 consecutive patients
undergoing SN mapping in biopsy confirmed primary cutane-
ous melanoma between September 1993 and January 1999.
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The patient group consisted of 135 men and 173 women aged
18 to 85 years (mean, 48). SN mapping was performed by a
triple technique, including lymphoscintigraphy followed by
blue dye and γ probe guided surgery.18 In our hospital, a com-
plete LND of the regional basin is performed in the case of a
tumour positive SN. Patients were screened for distant metas-
tases but none were found, so that LNDs were carried out in all
but two SN positive patients who refused to agree to the pro-
cedure. Within one year after the initial investigations, recur-
rences were diagnosed by the finding of distant metastases in
one patient within six months, and in another four patients in
the remaining period.
Pathology
Lymph nodes were fixed in neutral buffered formaldehyde.
SNs smaller than 0.5 cm were processed and paraffin wax
embedded intact, those between 0.5 and 1 cm were halved,
and SNs larger than 1 cm were lamellated into approximately
0.5 cm pieces.19 20 All SN blocks were step sectioned at five lev-
els with 250 µm intervals. On each level, sections were stained
with haematoxylin and eosin (H&E) and by immunohisto-
chemistry (S100 and HMB-45 antibodies). Lymph nodes in
LND specimens were analysed in a routine fashion, meaning
that one H&E stained section was made for each block, so that
depending on the size of the lymph node one to three sections
were obtained from each non-SN.
The size of the metastases was determined using an
interactive video overlay system (Q-PRODITR; Leica, Cam-
bridge, UK). The surface areas of individual tumour deposits
were measured and the total tumour area was calculated for
each node. Because tumour deposits are usually spherical,
surface areas were converted to diameter (mm) and volume
(mm3), as follows: diameter (d) = 2/(tumour area/pi) and
volume = 4/3pi(d/2)3. The total tumour volume for each nodal
basin was calculated by summing up the volumes of tumour in
all positive SN(s) and non-SN(s) in that basin.
It has been estimated that with a single central cross section
and immunostaining, 69% of metastases are found, as
opposed to 81% in the 10 step procedure used in SNs of
1 cm.21 In addition, with a limited number of slices, as used in
non-SNs, the slice may not contain the maximum diameter:
assuming that the section level is random, the average
measured diameter in the case of a single section will be
8.7 mm (in the middle between the maximum and minimum
diameter) in a spherical metastasis of 1 cm. In volume terms,
this implies a potential average underestimation of 34%. Com-
bined with the hit probability of 69%, this yields a mean
potential underestimation of the real tumour volume by 50%
(0.69* (1.0 − 0.34)) in non-SNs.
Statistical analysis
Logistic regression analysis was used to predict the usefulness
of PET: (1) at initial regional staging and (2) after a tumour
positive SN biopsy to identify patients with additionally
involved regional lymph nodes. In the first situation, we stud-
ied whether the established prognostic variables—age, sex,
Breslow thickness, and melanoma localisation—could predict
the presence of a PET detectable amount of tumour. In the
second situation, the feature “tumour volume in the SN” was
added to this set of variables. In both situations, a range of PET
detection limits was taken into account (2–10 mm). The
significance of the correlations was evaluated by Pearson’s
test. Tumour volumes in SNs and non-SNs were compared
with the Wilcoxon signed ranks test. Significance was set at
0.05.
RESULTS
Of 308 patients, 59 (19%) had a tumour positive SN (table 1).
SN positivity increased with Breslow thickness (table 1). In
addition, the amount of tumour in the SN was significantly
related to Breslow thickness (Pearson’s correlation coefficient
= 0.397; p = 0.002). Thirteen SN positive patients had
positive non-SNs, as shown by histological examination of 57
LND specimens and by (uneventful) follow up (at least two
years) in two patients who refused LND. A weak positive cor-
relation was found between the total amount of tumour in the
regional basin and the Breslow thickness of the primary
tumour (Pearson’s correlation coefficient = 0.286; p = 0.028).
Table 1 shows that the average size of tumour deposits in SNs
is extremely small, even in patients with Breslow thickness
> 4.0 mm.
For a state of the art PET scanner the detection rate for
metastases positive lymph nodes would be between 15% and
49% only. Figure 1 shows the predicted yield of scanners with
alternative resolution parameters (see also appendix 1).
Table 1 Tumour volumetry of regional lymph nodes in 59 patients with cutaneous
melanoma in relation to Breslow thickness and sentinel node status
Breslow thickness
(mm)
Patients with positive
SN(s)
Patients with positive
non-SN(s)*
Median total tumour volume
in regional node* basin (mm3)
(range)
0.76–1.5 19/122 (16%) 4/19 (21%) 0.01 (0.0001–118.86)
1.5–4.0 27/118 (23%) 5/27 (19%) 0.29 (0.0006–70.44)
>4.0 13/22 (59%) 4/13 (31%) 1.57 (0.004–55.06)
Total 59/308 (19%†) 13/59 (22%‡) 0.15 (0.0001–118.86)
*Assuming that the 2 patients refusing lymph node dissection (with uneventful follow up) had no involved
nodes; †95% confidence interval, 15% to 24%; ‡95% confidence interval, 12% to 34%.
Figure 1 The predicted yield of 18F-fluorodeoxyglucose positron
emission tomography (PET) scanners with different resolutions
(1–10 mm), using the histopathological data from 59 patients with
cutaneous melanoma and lymph node involvement. For each
resolution, the percentage of PET positive tumour basins is expressed
as a detection range corresponding to published target to
background ratios of 1.5–10 (appendix 1).12
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With logistic regression analysis, we found that no
established preoperative diagnostic indicator (age, sex, Bres-
low thickness, site of the primary melanoma) could predict
PET positivity at any presumed detection limit. However, if the
SN biopsy information (the tumour volume in the SN) was
included, the amount of tumour in the SN was the only
significant predictor for the presence of PET detectable
tumour in non-SNs, but only at detection limits of
< 65.4 mm3. It is predicted that at the 14.1 mm3 (3 mm)
detection limit (p = 0.006), PET will miss more than 29% of
the positive lymph nodes in patients with SN tumour volumes
exceeding 19 mm3.
DISCUSSION
Our present morphometric study shows that the average total
size of metastatic deposits in regional lymph node basins of
patients with cutaneous melanoma is quite small. Within a
broad range of detection limits for FDG-PET, most of these
deposits remain undetectable. Earlier claims that PET would
be of value12–15 have therefore been too optimistic.22 Large
patient studies to validate this conclusion in the clinical
setting would result in unnecessary costs. Such studies may
only be useful in a specific subset of patients—for example,
those with a large (> 19 mm3) tumour load in the SN.
This is the first study using histomorphometric data to pre-
dict the usefulness of a new imaging technique for a certain
indication. Instead of performing a traditional accuracy study,
we first assessed what could be expected from FDG-PET. Our
method provides a clear answer to this question and makes
further patient studies superfluous, which could save much
unnecessary cost. In addition, this method is probably useful
in other cancers with predictable lymphatic spread, such as
breast cancer, where similar optimistic expectations of PET
sensitivity have been postulated,11 but which have also been
challenged.16
The use of a “cumulative tumour volume” in separate
lymph nodes to represent the total tumour burden in the basin
obviously leads to some overestimation of PET sensitivity. On
the other hand, PET sensitivity may be underestimated
because of tissue shrinkage during fixation leading to reduced
volume measurements, and the fact that histopathology does
not identify 100% of tumour deposits,23 as explained in the
Methods section. However, we have tried to correct for this as
much as possible. A further refinement could have been to use
a sphere model approach instead of assuming that the metas-
tases are round, but it is unlikely that this would have
influenced the final results. Overall, we feel that our approach
has resulted in realistic tumour volume assessments and
resulting PET sensitivity estimations allowing a clear conclu-
sion.
“The average total size of metastatic deposits in regional
lymph node basins of patients with cutaneous melanoma
is quite small”
Our prediction of the value of PET for initial regional stag-
ing (fig 1) is in agreement with in vivo data of four
studies.24–27 The results of the study by Crippa et al,24 in which
23% of the nodal metastases < 5 mm were detected by PET,
are comparable because in our database 95% of the tumour
diameters were < 5 mm.
The SN status appears to be the most important prognostic
factor for recurrence,28 and the best method to select patients
with melanoma for adjuvant trials.29–31 Because FDG-PET is an
established method to monitor the early response to systemic
treatment, PET could then provide a tool to identify subclini-
cal tumours and to monitor their response to treatment in this
specific subset of SN positive patients. In our opinion, the next
step should be to study this specific subset of SN positive
patients and to perform LND regardless of the PET results.
PET scanning is unable to detect small metastatic deposits
in SNs of patients with primary melanoma. FDG-PET cannot
replace the SN biopsy, which is still the preferred method for
initial regional staging.
We conclude that morphometric analysis of metastatic load
predicts that PET scanning is unable to detect most metastatic
deposits in the sentinel and regional lymph nodes of patients
with cutaneous melanoma because these metastases are often
small. Therefore, the SN biopsy remains the preferred method
for initial regional staging. Thus, PET studies where patients
are scanned for this indication are superfluous.
APPENDIX 1 LESION DETECTABILITY IN EMISSION
TOMOGRAPHY
Detectability is a function of resolution and contrast. Accord-
ing to standard principles, at a 5 mm system resolution (R),
maximally 50% of the activity (emitted counts) from a lesion
of 5 mm diameter (D) will be registered because recovery (the
ratio between registered and emitted counts) is as follows: 1 −
exp[−ln2*(D/R)2].32 For various target to background (T/B)
ratios, the contrast resulting from this ratio and the resolution
of the imaging system can be determined because contrast =
1 + (T/B − 1)* recovery. In our model, we used an empirically
determined contrast of 1.1 as minimally required for
detection. Using the morphometric data, the expected
prevalence of FDG positive sites can then be predicted using
the reported in vivo target to background ratios for extratho-
racic and abdominal melanoma deposits (2–1012) and the
5 mm resolution typical of the present generation of PET
scanners.
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